Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia

Asian Pacific Journal of Tropical Biomedicine

Volumn 2, Issue 3, 2012, Pages 235-239

  Erko, Berhanu ^a   Degarege, Abraham ^a   Tadesse, Konjit ^a   Mathiwos, Asnake ^b   Legesse, Mengistu ^a  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b Hawassa College of Health Sciences   (Ethiopia)

Author keywords

Drug efficacy; Efficacy; Egg reduction; Ethiopia; Infection; Parasite; Praziquantel; Prevalence; Schistosoma mansoni; Schistosomiasis; Schoolchildren; Side effect; Susceptibility; Thick smear

Indexed keywords

PRAZIQUANTEL; ANTISCHISTOSOMAL AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; DYSURIA; ETHIOPIA; FATIGUE; FECES ANALYSIS; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HEMATOCHEZIA; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PREVALENCE; PRIMARY SCHOOL; PRIORITY JOURNAL; PRURITUS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHOOL CHILD; SINGLE DRUG DOSE; VOMITING; CROSS-SECTIONAL STUDY; FECES; PARASITOLOGY; STUDENT; YOUNG ADULT;

SCHISTOSOMA MANSONI;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; ETHIOPIA; FECES; FEMALE; HUMANS; MALE; PRAZIQUANTEL; PREVALENCE; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES; STUDENTS; YOUNG ADULT;

EID: 84858113558     PISSN: 22211691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2221-1691(12)60049-5     Document Type: Article

References (44)

1. Utzinger J, Raso G, Brooker S, De Savigny D, Tanner M, Ornbjerg N, et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 2009; 136: 1859-1874.
2. L o CT, Kloos H, Birrie H. The ecology of health and disease in Ethiopia. In: Ahmed ZZ, Kloos H, editors. Schistosomiasis. Addis Ababa: Ministry of Health; 1988, p. 196-213.
3. Coura JR. Control of schistosomiasis in Brazil: Perspectives and proposals. Mem Inst Oswaldo Cruz 1995; 90(2): 257-260.
4. WHO. The control of schistosomiasis: Second Report of the WHO Expert Committee. Tech Rep Ser 1993; 830: 1-86.
5. Webbe G, Jordan P. Human Schistosomiasis. In: Jordan P, Webbe G, Sturrock RF, editors. Control. Cambridge: CAB International; 1993, p. 05-435.
6. Keiser J, Vargas M, Vennerstrom JL. Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice. J Antimicrob Chemother 2010; 65: 1991-1995.
7. Keiser J, Chollet J, Xiao SH, Mei JY, Jiao PY, Utzinger J, et al. Mefloquine - an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 2009; 3: e350.
8. Xiao SH, Mei JY, Jiao PY. The in vitro effect of mefloquine and praziquantel against juvenile and adult Schistosoma japonicum. Parasitol Res 2009; 106: 237-246.
9. Manneck T, Haggenmiiller Y, Keiser J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitol 2010; 137: 85-98.
10. WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. WHO Expert Committee. Tech Rep Ser 2002; 912: 1-57.
11. Bergquist N. Schistosomiasis: from risk assessment to control. Trends Parasitol 2002; 18: 309-314.
12. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003; 19: 509-515.
13. Gryseels B, Stelma FF, Talk I, Van Dam GJ, Polman K, Sow S, et al. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geog Med 1994; 46: 209-219.
14. Stelma FF, Talla I, Sow S, Kongs A, Niang M, Polman K, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995; 63: 167-170.
15. Stelma FF, Sail S, Daff B, Sow S, Niang M, Gryseels B. Oxamniquine cures Schistosoma mansoni in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 1997; 176: 304-307.
16. G uisse F, Polman K, Stelma FF, Mbaye A, Talla I, Niang M, et al. Therapeutical evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in northern Senegal. Am J Trop Med Hyg 1997; 56: 511-514.
17. Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 1998; 92: 90-93.
18. Tchuem-Tchuente LA, Shaw DJ, Polla L, Cioli D, Vercruysee J. Efficacy of praziquantel against Schsitosoma haematobium infection in children. Am J Trop Med Hyg 2004; 71(6): 778-782.
19. Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol Res 2002; 90: 3-9.
20. De Clercq D, Vercruysee J, Kongs A, Verle P, Dompnier JP, Faye PC. Efficacy of artesuante and praziquantel in Schistosoma haematobium infected school children. Acta Trop 2002; 82: 61-66.
21. Kabatereine NB, Kemijumbi J, Ouma JH, Sturrock RF, Butterworth AE, Madsen H, et al. Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Trans R Soc Trop Med Hyg 2003, 97: 599-603.
22. WHO. Preventive chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva: WHO Press; 2006. [Online] Available from: http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf.
23. Geerts S, Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev 2000; 13(2): 207-222.
24. Erko B, Medhin G, Berhe N, Abebe F, Gebre-Michael T, Gundersen SG. Epidemiological studies on intestinal schistosomiasis in Wondo Genet, Southern Ethiopia. Ethiop Med J 2002; 40(1): 29-39.
25. WHO. Basic Laboratory Methods in Medical Parasitology.Geneva: World Health Organization; 1991. [Online] Available from: http://whqlibdoc.who.int/publications/9241544104_(part1).pdf.
26. D avis A. Antischistosomal drugs and clinical practice. In: Jordan P, Webbe G, Sturrock RF, editors. Human Schistosomiasis. Wallingford: CAB International; 1993, p. 367-404.
27. Wegner DHG. The profile of the trematodicidal compound praziquantel. Arzneim Forsch 1984; 34: 1132-1136.
28. Kumar V, Gryseels B. Use of praziquantel against schistosomiasis: a review of current status. Int J Antimicrob Agen 1994; 4: 313-320.
29. Yeneneh H, Abebe F, Birrie H, Ayele T. Praziquantel in the control of Schistosoma mansoni infection in Jiga, Northwestern Ethiopia. Ethiop J Health Dev 1996; 10(2): 105-110.
30. Degu G, Mengistu G, Jones J. Praziquantel efficacy against schistosomiasis mansoni in school children in North West Ethiopia. Trans R Soc Trop Med Hyg 2002; 96: 444-445.
31. Botros S, Sayeda H, Amera N, El-Ghannama M, Bennettb JL, Day TA. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int J Parasitol 2005; 35: 787-791.
32. Kihara JH, Muhoho N, Njomo D, MWObobia IK, Josyline K, Mitsui Y, et al. Drug efficacy of praziquantel and albendazole in school children in Mwea Division, Central Province, Kenya. Acta Trop 2007; 102: 165 - 171.
33. Scherrer AU, Sjöberg MK, Allangba A, Traoré M, Lohourignon LK, Tschannen AB, et al. Sequential analysis of helminth egg output in human stool samples following albendazole and praziquantel administration. Acta Trop 2009; 109: 226-231.
34. Galvão AF, Favre TC, Guimarães RJPS, Pereira APB, Zani LC, Felipe KT et al. Spatial distribution of Schistosoma mansoni infection before and after chemotherapy with two praziquantel doses in a community of Pernambuco, Brazil. Mem Inst Oswaldo Cruz 2010; 105: 555-562.
35. Polderman AM, Gryseels B, De Caluwt L. Cure rates and egg reduction in treatment of intestinal schistosomiasis with oxamniquine and praziquantel in Maniema, Zaire. Trans R Soc Trop Med Hyg 1988; 82: 115-116.
36. Raso G, N'Goran EK, Toty A, Luginbühl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Cote d'lvoire. Trans R Soc Trop Med Hyg 2004; 98: 18-27.
37. Katz N, Rocha RS, Chaves A. Preliminary trials with praziquantel in human infection due to Schistosoma mansoni. Bull World Health Organ 1979; 57: 781-784.
38. Tadesse K, Zein ZA. Comparison between the efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infections on a sugar estate in Ethiopia. Ann Trop Med Parasitol 1988; 82(2): 175-180.
39. Xiao SH, Catto BA, Webster LT. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 1985; 151: 1130-1137.
40. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 1986; 61: 294-303.
41. Silva LM, Menezes RM, de Oliveira SA, Andrade ZA. Chemotherapeutic effects on larval stages of Schistosoma mansoni during infection and re-infection of mice. Trans R Soc Trop Med Hyg 2003; 36: 335-341.
42. De Vlas SJ, Gryseels B. Underestimation of Schistosoma mansoni prevalences. Parasitol Today 1992; 8: 274-277.
43. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 2000; 5: 771-778.
44. Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, Gemetchu T. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north east Ethiopia. Acta Trop 1995; 72: 53-63.